New York: Zantac (ranitidine) litigation | DrugsMonitor.com
Zantac (ranitidine) litigation in New York (NY): Docket-era case primer, key legal deadlines, and a confidential review request today—not legal advice.
NDMA, ranitidine, recalled heartburn medication, cancer allegations, New York
Readers in New York (NY) should know the federal MDL in Florida largely dismissed claims in 2022; this page summarizes historical themes only and is not a guide to current filings.
Procedural history
MDL No. 2924 centralized federal Zantac product liability cases. Daubert and preemption rulings significantly narrowed or ended many federal claims.
A small number of state-court paths may exist for limited scenarios; individualized legal research is required.
FAQ
What is Zantac / Ranitidine litigation about?
This page summarizes public litigation context and safety background for Zantac (ranitidine) litigation. It is educational—not a case evaluation for you personally.
Is this page legal advice?
No. DrugsMonitor.com is not a law firm. Nothing here tells you whether you have a claim or what you should do next legally.
How do I request a confidential review?
Use the intake or "Request a confidential review" options on this page. That may route you to a partner firm only when you choose to proceed.